Background Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy

Similar documents
The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE**

Foreign Direct Investment in the Health Care Sector in Developing Countries Locations and Governance

COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN

2009 Results Highlights

Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch

The U.S. Climate for Switch 2010

SUPPLEMENTARY INFORMATION

The Brazilian Economy and the Pharmaceutical Market

Fraud in the Pharmaceutical Industry

About Deborah Wilkes

Investors Global Health Care Class

The Russian pharmaceutical market. Marina Veldanova Managing Director Polpharma Russia

Food supplements as part of the OTC Market

Overview of the Rx-to-OTC strategy, analyzing why, when, where, what and how to implement a switch strategy.

Pharmaceutical market structure

Prof. Claude Farrugia Vice President Communications, EIPG

Case No COMP/M RECKITT BENCKISER / BOOTS HEALTHCARE INTERNATIONAL. REGULATION (EC) No 139/2004 MERGER PROCEDURE

M&A Review of

IMS Retail Drug Monitor

Evaluation of Savings from Pharmaceutical Interventions. Robin Lunge Steve Kappel January 26, 2007

Introduction to the US Health Care System. What the Business Development Professional Should Know

Compliance in AIPM. Vladimir Shipkov AIPM Executive Director. Образец заголовка

Transparency guidelines and disclosure payments in the pharmaceutical industry

Healthcare Sector The Stock Market SIM, Professor West. Yiping Yang, Lu Yu

Drug Reimbursement - Croatia. Roganovic Jelena

HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007

Prescription Drug Coverage

INTERACTIONS BETWEEN THE PHARmaceutical

20+ Leading OTC Event 17+

Current trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

GCE A level 1083/01 BUSINESS STUDIES BS3

PPH VanEck Vectors Pharmaceutical ETF

Fair Pricing Coalition

MEDICARE PART D PRESCRIPTION DRUG PROGRAM BASICS

Notice of Incorporation of Holding Company through Sole-Share Transfer

QCU and Exercises for Part 2 : 20 QCU (only one answer is right) and 1 Exercise. Session 4 : Shares Session 5 : Bonds. Corporate Finance.

Your Medicines Supply Chain toolkit. Your NPA. Equipping you to survive and thrive

Nicholas Hall s Global OTC Markets The Definitive Guide to the World s 12 Leading OTC Markets

A Prescription for Investing in Health Care

Polar Capital Global Healthcare Growth and Income Trust

Indian Pharmaceutical Formulations Industry Report,

PHARMACY BENEFIT MANAGER (PBM)

Healthcare Report on Economic Position Combined Management Report 103. Margin (% of net sales) Business free cash flow 1, ,

Taiwan OTC market overview. The opportunities and challenges in OTC. Future outlook

Measuring the return from pharmaceutical innovation 2017 Methodology

2018 NACDS Annual Meeting Space Assignments (Numerical)

The Health Care Fortune Slide Series, Volume 57 February, 2018

Working Capital to Sales

Drug Deals in 2006: Cutting Edge Legal and Regulatory Issues in the Pharmaceutical Industry

Institutional Presentation. June/2016

Facts from IQVIA M Copyright 2017 IQVIA. All rights reserved.

Subject: Pharmacy Services & Formulary Management (Page 1 of 5)

BRISTOL MYERS SQUIBB CO

Profitable Growth : Why Acquisitions Matter at Least in Some Industries By: Dr. Thomas W. Schrepfer MBA, LL.M. PMIC Advisors Group Ltd.

State Action to Address Rising Prescription Drug Costs

Economic Sustainability Highlights

Generic Pharmaceuticals Market A Global Analysis

Ligand to Acquire Metabasis for Cash and Contingent Value Rights

7Y EUR Healthcare Performance Notes 06/21

Conflict of Interest Disclosure Form

SMART BETA REBALANCE SUMMARY USA SINGLE FACTORS

Market growth potential in Turkey: Short & medium term evaluation. Cem Baydar, Country Principal Istanbul, September, 2010

VIETNAM PHARMACEUTICAL INDUSTRY REPORT Q4/2017

Health Care in California: The Chronically Ill

Please also refer to the attached Investment Manager s July 2006 Monthly Portfolio Report.

Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes

Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2014

The Novasecta European MidPharma Report 2015

Evaluating and Determining Fair Market Value for KOLs. Presented by Jen Johnson, CFA August 10, 2011

FOR IMMEDIATE RELEASE 19 March 2010 A&D PHARMA HOLDINGS N.V. UNAUDITED FINANCIAL STATEMENTS FOR THE 12 MONTHS ENDED 31 DECEMBER 2009

fax. FAX completed and signed enrollment form to BMS Access Support at

FINANCIAL PERFORMANCE THREE-YEAR SUMMARY AS OF AND FOR THE YEAR ENDED DECEMBER 31 1


Scotia Private U.S. Dividend Class

Double-Digit Non-GAAP EPS Growth in Second Quarter 2011: Non-GAAP EPS of $0.95; GAAP EPS of $0.65

Merck & Co., Inc. Financial Highlights Package Third Quarter 2011

Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.

Summary of the financial reports for Johnson & Johnson from

FREE ARTICLE. Russian pharmaceutical market overview. Source: Pharma Poland News

Pharmaceutical Management Commercial Plans

Annual report Putnam VT Global Health Care Fund

Hikma Pharmaceuticals PLC

COMPANY PROFILE SEPTEMBER 2010

Global Top 100 Companies by market capitalisation

Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2012

Ukrainian Pharmaceutical Market

Russian market at a crossroads: still emerging and attractive, despite going through hard times

Value of Consumer Health Products The Impact of Switching Prescription Medications to Over-the-Counter

Press Release. ALTANA continues its sustained success ALTANA AG

Amerigroup Medicare Member PBM Conversion Talking Points

Health Care Resources: Costs. Peterson-Kaiser Health System Tracker

Stability Shelf Life Working Group

Profitable Growth : Why Acquisitions Matter at Least in Some Industries

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

Pharmacare Programs Audit Guide September 1, 2017

Evaluation of Patient Assistance Program Eligibility and Availability for Top 200 Brand Name and Generic Drugs in the United States

New Models, New Metrics for Generics. IGPA Conference Montreal October 1 st 2009

Contents THE MERGERS AND ACQUISITIONS ENVIRONMENT

Transcription:

CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Background Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy o Life Expectancy o Birth Rates o Tobacco Use o Obesity Declining Growth of the World Population Prescription vs. Over-the-Counter Industry o Rx-to-OTC Switch Industry o Rx-to-OTC Switch Forecast in the United States Economic Trends o Purchasing Power Trends o U.S. Healthcare Market o U.S. Healthcare Challenges Health Insurance Issues and Trends o Healthcare Flexible Spending Accounts and OTC Medicines Consumer Issues and Trends o U.S Consumers o Consumers Around the World Access to Professional Medical Services and the Link to Self-Medication o Online Resources for Health Information Regulatory Environment o Revisions to Pharmaceutical Affairs Law (PAL) in Japan o Russian Beneficiary Drug Provision Program o A Third Class of Drugs in the United States CHAPTER THREE: OTC MARKETS IN ASIA-PACIFIC AND AFRICA

CHAPTER FOUR: OTC MARKETS IN EUROPE CHAPTER FIVE: OTC MARKETS IN NORTH AMERICA CHAPTER SIX: OTC MARKETS IN SOUTH AMERICA CHAPTER SEVEN: SUMMARY OF WORLD OTC MARKETS CHAPTER EIGHT: LEADING OTC MANUFACTURERS Competitor Analysis Significant Agreements, Mergers and Acquisitions o Procter & Gamble and Teva Pharmaceutical Industries o Sanofi and Chattem Consumer o Schering-Plough and Merck & Co. o Wyeth and Pfizer o Reckitt Benckiser and Adams Respiratory Therapeutics o Bristol-Myers Squibb and Novartis AG o Johnson & Johnson and Pfizer o Reckitt Benckiser and Boots Healthcare

o Bayer and Roche Leading Corporate Profiles o Bayer Healthcare Ag o Boehringer Ingelheim Gmbh o Glaxosmithkline o Mc Neil Consumer o (A Johnson & Johnson Company) o Merck o Novartis Consumer o Pfizer o Procter & Gamble o Reckitt Benckiser o Sanofi o Taisho Pharmaceutical APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY Table 1-1 5: Total World OTC, 2007-2015 Figure 1-1 : Total World OTC : 2007-2015 CHAPTER TWO: INTRODUCTION Table 2-1 : Average Life Expectancy in Years by Country 1980, 2004 and 2011 Figure 2-1 : Average Life Expectancy in Years by Country 1980 and 2011 Table 2-2 : Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected 2012 and 2020 Table 2-3 : Percent of Smokers by Country Figure 2-2 : Average Percent of Smokers Worldwide in Developed Regions Table 2-4 : Percent of Obese* Population, 2008 Table 2-5 : World Population 1980 to 2050 Figure 2-3 : World Population 1980 to 2050 Table 2-6 : Total Pharmaceutical Markets, Prescription vs. Non-Prescription by Country, 2011 Figure 2-4 : Total Pharmaceutical Markets, Prescription vs. Non-Prescription by Country, 2011 Table 2-7 : Leading FDA Approved Rx-to-OTC Switches, 1994-2011 Figure 2-5 : Number of New Rx-to-OTC Switches in the United States, per Year 1976-2011 Table 2-8 Table 2-9 : Potential Rx-to-OTC Switches, 2012-2015 Table 2-9 : P otential Rx-to-OTC Switches, 2012-2015 Table 2-10 : Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009

Figure 2-6 : Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2006 Table 2-11 : Gross National Income Comparison by Country 2000-2010 Figure 2-7 : Gross National Income Growth by Country 2000-2010 Table 2-12 : National Healthcare Expenditures in the United States 1960-2015 Figure 2-8 : Healthcare Spending as a Percent of GDP in the United States Table 2-13 : Health Insurance Trends in the United States 2005-2009 Table 2-14 : Practicing Physicians per 1,000 Population by Country, 2000-2008 Figure 2-9 : Internet Users per 100 Inhabitants, 2010 Figure 2-10 : Typical Pharmacist-Consumer OTC Drug Counseling Session CHAPTER THREE: OTC MARKETS IN ASIA-PACIFIC AND AFRICA Table 3-1 : Total Midyear Population by the Five Most Populated Countries in Asia- Pacific, 2005-2025 Figure 3-1 : Total Midyear Population by the Five Most Populated Countries in Asia- Pacific, 2005, 2015, and 2025 Table 3-2 : Total Midyear Population in Africa by Region, 1995-2025 Figure 3-2 : Total Midyear Population for Africa by Region, 2005, 2015, and 2025 Table 3-3 : Examples of Marketed OTC Products in Asia-Pacific and Africa (Product Name by Type and Marketer) Table 3-4 : Asia-Pacific/Africa OTC Market as a Percentage of World Market, 2007, 2011 and 2015 Figure 3-3 : Asia-Pacific/Africa OTC Market as a Percentage of World Market, 2011 Figure 3-4 : Asia-Pacific/Africa OTC Market as a Percentage of World Market, 2015 Table 3-5 : Asia-Pacific/Africa OTC, 2007-2015 Figure 3-5 : Asia-Pacific/Africa OTC : 2007-2015 Table 3-6 : Asia-Pacific/Africa OTC by Product Segment, 2007-2015 Figure 3-6 : Asia-Pacific/Africa OTC by Product Segment, 2007-2015 Figure 3-7 : Asia-Pacific/Africa OTC by Product Segment, 2011 Table 3-7 : Asia-Pacific/Africa OTC by Selected Country, 2011 Figure 3-8 : Asia-Pacific/Africa OTC by Selected Country, 2011 CHAPTER FOUR: OTC MARKETS IN EUROPE Table 4-1 : Total Midyear Population by the Five Most Populated Countries in Europe, 2005-2025 Figure 4-1 : Total Midyear Population by the Five Most Populated Countries in Europe, 2005, 2015, and 2025 Table 4-2 : Examples of Marketed OTC Products in Europe (Product Name by Type and Marketer) Table 4-3 : European OTC Market as a Percentage of World Market, 2007, 2011 and 2015 Figure 4-2 : European OTC Market as a Percentage of World Market, 2011 Figure 4-3 : European OTC Market as a Percentage of World Market, 2015 Table 4-4 : European OTC, 2007-2015

Figure 4-4 : European OTC : 2007-2015 Table 4-5 : European OTC, Markets by Product Segment, 2007-2015 Figure 4-5 : European OTC, Markets by Product Segment, 2007-2015 Figure 4-6 : European OTC by Product Segment, 2011 Table 4-6 : European OTC by Selected Country, 2011 Figure 4-7 : European OTC by Selected Country, 2011 CHAPTER FIVE: OTC MARKETS IN NORTH AMERICA Table 5-1 : Total Midyear Population by the Five Most Populated Countries in North America, 2005-2025 Figure 5-1 : Total Midyear Population by the Five Most Populated Countries in North America, 2005, 2015, and 2025 Table 5-2 : Examples of Marketed OTC Products in North America (Product Name by Type and Marketer) Table 5-3 : North American OTC Market as a Percentage of World Market, 2007, 2011 and 2015 Figure 5-2 : North American OTC Market as a Percentage of World Market, 2011 Figure 5-3 : North American OTC Market as a Percentage of World Market, 2015 Table 5-4 : North American OTC, 2007-2015 Figure 5-4 : North American OTC : 2007-2015 Table 5-5 : North American OTC by Product Segment, 2007-2015 Figure 5-5 : North American OTC by Product Segment, 2007-2015 Figure 5-6 : North American OTC by Product Segment, 2011 Table 5-6 : North American OTC by Selected Country, 2011 Figure 5-7 : North American OTC by Selected Country, 2011 CHAPTER SIX: OTC MARKETS IN SOUTH AMERICA Table 6-1 : Total Midyear Population by the Five Most Populated Countries in South America, 2005-2025 Figure 6-1 : Total Midyear Population by the Five Most Populated Countries in South America, 2005, 2015, and 2025 Table 6-2 : Examples of Marketed OTC Products in South America (Product Name by Type and Marketer) Table 6-3 : South American OTC Market as a Percentage of World Market, 2007, 2011 and 2015 Figure 6-2 : South American OTC Market as a Percentage of World Market, 2011 Figure 6-3 : South American OTC Market as a Percentage of World Market, 2015 Table 6-4 : South American OTC, 2007-2015 Figure 6-4 : South American OTC : 2007-2015 Table 6-5 : South American OTC by Product Segment, 2007-2015 Figure 6-5 : South American OTC by Product Segment, 2007-2015 Figure 6-6 : South American OTC by Product Segment, 2011 Table 6-6 : South American OTC by Selected Country, 2011 Figure 6-7 South American OTC by Selected Country, 2011

CHAPTER SEVEN: SUMMARY OF WORLD OTC MARKETS Table 7-1 : Total World OTC, 2007-2015 Figure 7-1 : Total World OTC : 2007-2015 Table 7-2 : Total World OTC, Markets by Product Segment, 2007-2015 Figure 7-2 : Total World OTC, Markets by Product Segment, 2007-2015 Figure 7-3 : Total World OTC by Product Segment, 2011 Figure 7-4 : Total World OTC by Product Segment, 2015 Table 7-3 : Top Ten World OTC Markets by Country, 2011 Figure 7-5 : Top Ten World OTC Markets by Country, 2011 CHAPTER EIGHT: LEADING OTC MANUFACTURERS Table 8-1 : Leading Suppliers Shares of the OTC Market by Estimated Revenues 2009, 2010 and 2011 Figure 8-1 : Leading Suppliers Shares of the OTC Market, 2009 Figure 8-2 : Leading Suppliers Shares of the OTC Market, 2010 Figure 8-3 : Leading Suppliers Shares of the OTC Market, 2011